The Center for Translational Molecular Medicine (CTMM) is a large public-private partnership that aims to translate science into better healthcare. CTMM represents a multi-institutional research initiative to stimulate the development of technologies in the area of oncology, cardiovascular, neurodegenerative and infectious / auto-immune diseases. We operate by inviting, assessing, funding, monitoring and adjusting multidisciplinary projects that involve active participation by Netherlands-based academia and industry. Currently (December 2014) 126 partners are involved and more than 1.940 FTE are or have been active in 25 projects ending December 2015. The total allocated budget amounts to 311.4 M Euro. CTMM is funded by the Dutch government (50%), academia (25%) and industry (25%). Preparations have been started for a merger of CTMM and TI Pharma in 2015, creating a new centre of expertise equipped to make the most of the growing interdependence of medicines and medical technology.